Allergan Press Releases

DUBLIN, Aug. 21, 2018 /PRNewswire/ -- Allergan plc (NYSE: AGN) today announced it received a Complete Response Letter (CRL) from the U.S. Food and Drug Administration (FDA) in response to the New Drug Application (NDA) for ulipristal acetate (UPA) for the treatment of abnormal uterine bleeding in women with uterine fibroids.

DUBLIN, Aug. 8, 2018 /PRNewswire/ -- Allergan plc (NYSE: AGN) today announced that Michael E. Greenberg, PhD will join its Board of Directors effective immediately, as part of the company's ongoing board refreshment process. Dr. Greenberg is the Nathan Marsh Pusey Professor of Neurobiology at Harvard University and the Co-Lead of the Allen Discovery Center for Human Brain Evolution at Harvard Medical School. He brings a nearly 35-year track record of groundbreaking scientific discoveries in neurobiology to Allergan's Board.

DUBLIN and CAMBRIDGE, Mass., Aug. 6, 2018 /PRNewswire/ -- Allergan plc (NYSE: AGN), a leading global pharmaceutical company, and Editas Medicine, Inc. (NASDAQ: EDIT), a leading genome editing company, today announced that Allergan's wholly-owned subsidiary, Allergan Pharmaceuticals International Limited (Allergan), has exercised its option to develop and commercialize EDIT-101 globally for the treatment of LCA10. Additionally, the two companies announced that Editas Medicine has exercised its option to co-develop and share equally in the profits and losses from EDIT-101 in the United States. Under the terms of the option agreement signed in March 2017, Allergan has paid Editas Medicine a fee of $15 million in conjunction with the exercise of its option. Editas Medicine is eligible to receive an additional $25 million from Allergan upon acceptance of an investigational new drug (IND) application for EDIT-101 by the Food & Drug Administration (FDA). 

DUBLIN, July 30, 2018 /PRNewswire/ -- Allergan plc (NYSE: AGN) today announced the record and payment dates for a cash dividend of $0.72 per ordinary share for the third quarter of 2018. The dividend will be paid on September 17, 2018 to shareholders of record at the close of business on August 17, 2018.

DUBLIN, July 26, 2018 /PRNewswire/ -- Allergan plc (NYSE: AGN) today reported its second quarter 2018 performance. Total second quarter 2018 GAAP net revenues were $4.12 billion, a 2.9 percent increase from the prior year quarter. SECOND QUARTER 2018   Executive Commentary
"Allergan's performance in the first half of 2018 demonstrates the strength of our strategy and a sharp focus on execution. We have driven strong growth in our key products and core business, delivered seven successful pivotal clinical trials for our key R&D programs and executed on our capital deployment strategy," said Brent Saunders, Chairman and CEO of Allergan.

DUBLIN, July 23, 2018 /PRNewswire/ -- Allergan plc (NYSE: AGN), a leading global pharmaceutical company, today announced the U.S. Food and Drug Administration has granted Fast Track  designation for AGN-241751, an investigational new treatment for Major Depressive Disorder (MDD).  AGN-241751 is a novel, oral, rapid-acting anti-depressant that recently entered Phase 2 development.  

DUBLIN, July 19, 2018 /PRNewswire/ -- Allergan plc, (NYSE: AGN), a leading global pharmaceutical company and Molecular Partners (SIX: MOLN), a clinical-stage biopharmaceutical company developing a new class of drugs known as DARPin® therapies, today announced the release of two positive clinical trials, SEQUOIA and  CEDAR for abicipar, demonstrating that both the 8-week and 12-week treatment regimens met the pre-specified primary endpoint of non-inferiority to ranibizumab. SEQUOIA and CEDAR are identical global phase 3 studies designed to assess the efficacy and safety of abicipar compared with ranibizumab in treatment-naïve patients with neovascular age-related macular degeneration (AMD).  The primary endpoint measured the proportion of treated patients with stable vision at week 52.

DUBLIN, July 10, 2018 /PRNewswire/ -- Allergan plc (NYSE: AGN), a leading global pharmaceutical company, today announced the launch of a new over-the-counter (OTC) artificial tear formulation, REFRESH^® REPAIR Lubricant Eye Drops. The first and only artificial tear in the U.S. formulated with carboxymethylcellulose (CMC), hyaluronic acid (HA, an inactive ingredient), and osmoprotectants, REFRESH^® REPAIR is the latest addition to the REFRESH^® portfolio, the number one doctor-recommended brand of artificial tears. REFRESH^® REPAIR tears are designed to repair and protect the eyes from the harmful effects of dry eye and improve clarity of vision.

DUBLIN, June 28, 2018 /PRNewswire/ -- Allergan plc, (NYSE: AGN), a leading global pharmaceutical company, announced today that the Company's sponsored CaMEO (Chronic Migraine Epidemiology and Outcomes) study is being recognized with the 2018 Harold G. Wolff Lecture Award for its continued commitment to understanding the natural disease course of migraine with the acceptance of the manuscript, "Identifying Natural Subgroups of Migraine Based on Comorbidity and Concomitant Condition Profiles: Results of the Chronic Migraine Epidemiology and Outcomes (CaMEO) Study" to Headache. The American Headache Society awards the Harold G. Wolff Lecture Award to the best manuscript on headache, head or face pain, or the nature of pain itself. Allergan has been a leader in Chronic Migraine research for over 20 years and sponsored CaMEO to support the clinical community by generating data to characterize natural disease course, quantify individual, economic, societal and familial impact of life with migraine, specifically Chronic Migraine, and to provide evidence-based foundation to improve Chronic Migraine management. 

DUBLIN, June 26, 2018 /PRNewswire/ -- Allergan plc (NYSE: AGN) today announced that it intends to release second quarter 2018 financial results on Thursday, July 26, 2018, prior to the open of U.S. financial markets. Allergan will host a conference call and webcast at 8:30 a.m. Eastern Time on Thursday, July 26, 2018 to discuss its financial results. The dial-in number to access the call is U.S./Canada (877) 251-7980, International (706) 643-1573, and the conference ID is 67781714.